miRNA (100 ng) or mRNA (200 ng) were reverse transcribed to cDNA, using Taqman MicroRNA Reverse Transcription reagent or High Capacity cDNA Reverse Transcription Kit (Applied Biosystems). Predeveloped primer/probe sets were purchased from Applied Biosystems (TaqMan miRNA assays or TaqMan gene assays). The quantitative fluorogenic amplification of cDNA (RT-qPCR) was performed using an ABI 7500 Real Time PCR (Applied Biosystems) or Eppendorf RealPlex (Eppendorf) instruments, respectively. RNU44 (based on manufacturer’s recommendations (Applied Biosystem) and previous reports [38 (link), 39 (link)]) or ribosomal RNA (18S) [40 (link), 41 (link)] was used as the reference miRNA or gene, respectively. The cycle threshold (Ct) value obtained was normalized to that of the RNU44 or 18S gene (∆Ct). Data were expressed as 2-∆∆Ct [42 (link)] where ∆∆Ct was calculated from subtracting individual ∆Ct from ∆Ct of non-asthmatic media control at baseline.
Free full text: Click here